Navigation Links
Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
Date:12/5/2013

BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-small-cell lung cancer (NSCLC), biomarker testing is already widely employed in the China and South Korea markets, and is set to increase to European levels in the next two years.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Decision Resources' new Emerging Markets Physician & Payer Forum report entitled NSCLC in China and South Korea: Physician and Payer Perspectives on Prescribing Trends, Patient Access, and Reimbursement Challenges Facing Current and Emerging Therapies finds that surveyed oncologists in China (most of whom practice in Tier 3 hospitals) estimate that one-half of their NSCLC patients are currently tested for EGFR mutations, and that by year-end 2016 almost three-quarters will be tested. ALK–translocation testing rates are currently low, at around one-fifth of patients, but will increase even more dramatically in the next three years. Pfizer's Xalkori, an oral, dual inhibitor of ALK and c-Met, was the first targeted agent to be approved for NSCLC with a companion diagnostic test. On the basis of impressive overall response data, Xalkori received regulatory approval in China in January 2013 and became available in a number of regions about six months later. Lack of reimbursement for testing and the high cost treatment are the key barriers to testing in China, but surveyed oncologists also point to lack of patient willingness to be tested.

In South
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
2. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
3. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
4. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
5. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
6. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
7. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
8. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
9. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
10. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
11. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... 11, 2014 Neurelis, Inc. ("Neurelis") today announced ... the option held by Biotie to purchase Neurelis, clearing ... NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients ... past year, Biotie has advanced the development program for ... pivotal clinical work required for NDA submission to the ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... N.J., Oct. 25, 2011 Omthera Pharmaceuticals, Inc., a ... J. Maines has joined the Company as Vice President ... to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines ... at Omthera.   Mr. Maines brings to ...
... N.C., Oct. 25, 2011 GlaxoSmithKline, one of ... today announced the 10 winners of its GlaxoSmithKline ... Philadelphia-area healthcare nonprofit organizations will receive $400,000 in ... the underserved in their communities. Three ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:7/13/2014)... (PRWEB) July 14, 2014 Worldwide ladies ... selection. Angeldress.co.uk has taken a different approach and ... fresh items are offered in more colour choices that ... a famous brand of women’s special occasion apparels. The ... Its dress specialists are working hard to create the ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Ticket Down ... Real Madrid Tickets . For the fifth straight year ... Cup will be held at American stadiums this summer. The ... on American soil. The eight teams are split into two ... stage, the top two teams will compete to become champion. ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The North American ... million in 2013 to $5,450 million by 2018, at a ... systems market is expanding at a rapid pace in North ... ever tightening laws on water & wastewater storage and collection, ... infrastructure. The market is expanding at a healthy rate in ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... more respectful, SAN DIEGO, March 19 Over one-third ... to three years, find a non-nursing,job, work part-time, or work ... AMN Healthcare, the largest health care staffing firm in,the country, ... baby,boomer nurses may be facing career burn-out. About 46 percent ...
... fast and precise ... ALTO, Calif., March 19 Varian Medical,Systems (NYSE: ... centers in North,America and Europe to further the development ... fast and precise,cancer treatments. RapidArc makes it possible to ...
... Names New President and CEO, MIAMI, March 19 ... (NPF) announced today that Joyce A.,Oberdorf has been named ... was most recently Vice President, Policy, Planning,and Communications at ... "Ms. Oberdorf is an outstanding choice to help NPF ...
... Johnson & Johnson Vision ... Contact Lenses, JACKSONVILLE, Fla., March 19 Johnson ... the ACUVUE(R) The Difference is,Real(TM) Trip to Beijing Sweepstakes, ... performance. The sweepstakes runs March 18,through April 11, 2008, ...
... China, March 19 /Xinhua-PRNewswire-FirstCall/ -- China,Nepstar Chain Drugstore Ltd. ... largest drugstore chain in China based on the number ... the,quarter and fiscal year ended December 31, 2007., ... December 31, 2007: -- Revenues increased 9.5% to ...
... Mustang at the New York, International Auto Show to raise money for breast ... ... Komen Race for the Cure - to $500 for ... more than $95 million in, cash and in-kind contributions for breast cancer education and ...
Cached Medicine News:Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 3Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 4Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 5Health News:National Parkinson Foundation Announces Its New President and CEO 2Health News:National Parkinson Foundation Announces Its New President and CEO 3Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 2Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 2Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 4Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 5Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 6Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 7Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 8Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 9Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 10Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 11Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 12Health News:Ford Launches 'Warriors in Pink' Mustang for '09, Doubles Contributions To Race For The Cure 2
Zero clearance, front breathing, undercounter refrigeration system....
Designed to meet the requirements of reagent grade water for routine analysis....
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: